HC Wainwright Has Lowered Expectations for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price

TriSalus Life Sciences (NASDAQ:TLSI) had its price objective decreased by analysts at HC Wainwright from $12.00 to $10.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright‘s price target points to a potential upside of 250.88% from the stock’s current price.

A number of other analysts have also commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Wednesday, November 4th. Guggenheim set a $12.00 price objective on shares of TriSalus Life Sciences in a research report on Wednesday, September 23rd. Canaccord Genuity Group set a $4.00 target price on shares of TriSalus Life Sciences in a report on Tuesday. Zacks Research raised shares of TriSalus Life Sciences to a “hold” rating in a research report on Thursday, September 10th. Finally, Citigroup reiterated a “buy” rating on shares of TriSalus Life Sciences in a research note on Tuesday. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, TriSalus Life Sciences presently has an average rating of “Moderate Buy” and an average target price of $9.20.

TriSalus Life Sciences Stock Down 11.5%

TriSalus Life Sciences stock opened at $2.85 on Wednesday. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05. TriSalus Life Sciences has a one year low of $2.20 and a one year high of $7.95. The business’s fifty day moving average is $4.21 and its 200 day moving average is $4.34.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $12.88 million during the quarter, compared to the consensus estimate of $14.02 million. Equities analysts anticipate that TriSalus Life Sciences will post -0.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TriSalus Life Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. White Pine Capital LLC bought a new position in shares of TriSalus Life Sciences in the 3rd quarter worth approximately $2,143,000. Royce & Associates LP purchased a new stake in TriSalus Life Sciences during the third quarter valued at approximately $862,000. Russell Investments Group Ltd. purchased a new stake in TriSalus Life Sciences during the third quarter valued at approximately $68,000. Provenance Wealth Advisors LLC purchased a new stake in TriSalus Life Sciences during the third quarter valued at approximately $94,000. Finally, CWA Asset Management Group LLC bought a new position in TriSalus Life Sciences in the third quarter worth approximately $310,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences News Roundup

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: TriSalus reported third-quarter revenue growth of 11.3% to $12.9 million. Management outlined a 2026 revenue outlook of $46 million to $48 million, while TriNav Advance clearance was cited as a potential growth driver in 2027. Article: TriSalus outlines 2026 revenue outlook and growth drivers
• Neutral Sentiment: A short-interest report stated that short interest totaled zero shares as of November 10, offering no clear indication of notable short-selling pressure. TriSalus Life Sciences stock information
• Negative Sentiment: Quarterly results fell short of consensus: TriSalus reported a loss of $0.15 per share versus the expected $0.13 loss, and revenue of $12.88 million versus estimates of $14.02 million. The revenue shortfall and larger-than-expected loss may weigh on investor sentiment despite year-over-year growth. Article: TriSalus reports third-quarter results

About TriSalus Life Sciences

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches. Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply. TriSalus offers interventional oncology devices, including the TriNav Infusion System, which is designed to support localized delivery of treatments while helping limit drug diversion away from the targeted tumor.